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BACKGROUND: The role of further hormone therapy in castration-resistant prostate cancer (CRPC) remains unclear. We performed a
multi-centre randomised phase III study comparing the use of Dexamethasone, Aspirin, and immediate addition of Diethylstilbestrol
(DAiS) vs Dexamethasone, Aspirin, and deferred (until disease progression) addition of Diethylstilbestrol (DAdS).
METHODS: From 2001 to 2008, 270 men with chemotherapy-naive CRPC were randomly assigned, in a 1:1 ratio, to receive either
DAiS or DAdS. They were stratified for performance status, presence of bone metastases, and previous normalisation of prostate-
specific antigen (PSA) to androgen deprivation. The study end points were the proportion of patients achieving a 50% PSA response,
progression-free survival (PFS), overall survival, and quality of life. Intention-to-treat analysis was carried out. The effect of treatment
was studied first by Kaplan–Meier curves and log-rank test, and finally through multivariable stratified Cox’s proportional hazards
model adjusting for the effects of possible baseline prognostic factors. Quality of life was analysed using multivariate analysis of
variance.
RESULTS: At study entry, the median age was 76 years (inter-quartile range: 70–80 years), the median PSA was 79ngml
 1, and 76% of
the cohort had metastatic disease. The response rates for DAiS (68%) and DAdS (64%) were not significantly different (P¼0.49).
Similar to the response rate, neither the PFS (median¼8.1 months for both arms) nor the overall survival (19.4 vs 18.8 months)
differed significantly between the DAiS and DAdS groups (P40.20). However, the response rate for the DAiS (68%) was significantly
higher than the response rate of DA (before adding Diethylstilbestrol) (50%) (P¼0.002). Similarly, the median time to progression
for DAiS (8.6 months) was significantly longer than that of DA (4.5 months) (Po0.001). Multivariable analysis showed that patients
with previous haemoglobin X11gdl
 1 decreased the risk of death significantly (hazard ratio: 0.44, 95% CI: 0.25–0.77). Patients
treated with previous anti-androgens alone had more than 5 times more risk of death compared with patients treated with
gonadorelin analogues throughout their castration-sensitive phase. Treatment sequencing did not affect the quality of life but pre-
treatment performance status did. The incidence of veno–thromboembolic events was 22% (n¼28) in DAiS and 11% (n¼14) in
the DA arm (P¼0.02). Painful gynaecomastia occurred in only 1% on DA, whereas in 40% on DAiS (P¼0.001).
CONCLUSION: Dexamethasone and immediate Diethylstilbestrol resulted in neither higher PSA response rate nor higher PFS
compared with Dexamethasone with deferred Diethylstilbestrol. There was no suggestion of significantly improved overall survival or
quality of life. Given the significantly higher toxicity of Diethylstilbestrol, deferring Diethylstilbestrol until failure of Dexamethasone is
the preferred strategy when using these agents in CRPC.
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Prostate cancer is the most common cancer in men in Europe and
in the United States. The frequency of patients presenting with
disease has risen following the introduction of the prostate-specific
antigen (PSA) blood test. The management of locally advanced or
metastatic disease is initially carried out with androgen deprivation
therapy, in the form of bilateral orchidectomy or gonadorelin
analogues (GnRHs), with or without a peripheral anti-androgen
(AA) (Hellerstedt and Pienta, 2002)) with the addition of radio-
therapy to the prostate in those with locally advanced disease
(Mottet et al, 2010; Warde et al, 2010). When this treatment fails,
usually after 1–3 years, the disease is termed castration-resistant
prostate cancer (CRPC) (Scher et al, 2008)), and the use of further
endocrine agents and/or chemotherapy is common. Chemotherapy
has been shown to improve symptoms (Tannock et al, 1996), and
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sdocetaxel (Petrylak et al, 2004; Tannock et al, 2004), in particular,
has more recently been shown to prolong life by 2–3 months
compared with mitoxantrone. The lack of robust randomised data
regarding the timing and choice of further endocrine agents in this
setting has resulted in no clear consensus.
A randomised study has confirmed that prednisone is superior
to flutamide in terms of quality of life (Fossa et al, 2001). Further
phase II studies have suggested that Dexamethasone results in
superior PSA responses (the proportion of patients achieving a
50% reduction in PSA) (Nishimura et al, 2000; Venkitaraman et al,
2008) when compared with that observed with either prednisone/
prednisolone (Tannock et al, 1996) or hydrocortisone (Kantoff
et al, 1999). Whether this translates to a survival advantage over
other steroids is unclear.
Oestrogens are clearly active in prostate cancer and were
originally thought to function by inducing androgen deprivation
indirectly. The xeno-oestrogen Diethylstilbestrol has been the most
widely investigated oestrogen. More recently it has been observed
that this drug is active in CRPC (Farrugia et al, 2000), the
mechanism of this may include binding to the androgen receptor.
However, Diethylstilbestrol has significant side effects, which has
limited its use. These include veno–thromboembolic events
(VTEs), cardiac failure, stroke, and gynaecomastia.
The combination of corticosteroids and low-dose Diethylstil-
bestrol (1mg per day) is active in CRPC (Farrugia et al, 2000). The
optimal timing of the two drug groups had not been elucidated.
We therefore conducted a pragmatic randomised phase 3 trial in
locally advanced or metastatic disease to see whether the drugs
should be given concurrently or in sequence. As aspirin is
frequently given in an attempt to reduce the risk of VTEs, yet
inhibiting cyclooxygenase 2 might inhibit prostate cancer growth
(Yoshimura et al, 2000); it was decided that those patients
allocated to steroids alone would receive aspirin, to counter the
criticism that any benefit of Diethylstilbestrol were in fact because
of aspirin rather than to the Diethylstilbestrol.
Our objective in this trial was to compare the immediate vs
deferred addition of Diethylstilbestrol with Dexamethasone and
aspirin in treating patients with CRPC. The comparison was done
in terms of response rate, time to progression, progression-free
survival (PFS), overall survival, and quality of life. As patients with
CRPC form a very heterogeneous group, stratified randomisation
was carried out on the basis of three established factors.
PATIENTS AND METHODS
Study design
This was a multi-centre, randomised, open-label phase III trial to
compare two treatment strategies in patients with newly diagnosed
CRPC: the trial compared the use of Dexamethasone, Aspirin, and
immediate addition of Diethylstilbestrol (DAiS) vs Dexametha-
sone, Aspirin, and deferred (until disease progression) addition of
Diethylstilbestrol (DAdS). The study was approved by a multi-
centre research ethics committee with local ethical approval sought
by each recruiting centre. All patients gave written informed
consent before enrolling in the study. Patients were randomised to
the trial with a 1:1 ratio by stratifying according to performance
status (ECOG: 0 vs 1–3), whether or not they achieved a PSA
o4.5ngml
 1 with initial androgen deprivation, and whether or
not they had a positive or negative bone scan before study entry.
The study was performed in accordance with the Declaration of
Helsinki as well as with the Good Clinical Practice Guidelines.
Patient population
Criteria for patients to enter the study population were as follows:
they had to have a diagnosis of prostate cancer, be over 18 years
old, and have an ECOG performance status 0–3. They were also
required to be biochemically castrate (testosterone o1.5nmolml
 1
or if not to have failed the addition of a peripheral AA), have a
PSA 45ngml
 1, and disease progression determined by rising
PSA and/or progression of symptoms, that is, increasing pain from
documented bone metastases, despite stable but elevated PSA.
Patients required adequate bone marrow reserve (WBC 43 10
9
per litre and platelets 450 10
9 per litre) and adequate liver
function (bilirubin less than 2  upper limit of normal and ALT
or AST less than 3  upper limit of normal).
The following were exclusion criteria for the study – those with
previous thrombombolic disease (including stroke), angina, and
poorly controlled diabetes mellitus. Previous uncomplicated
myocardial infarction was not an exclusion criterion. It was up
to the individual site to decide whether or not to continue GnRH,
once starting the study. Once a site had decided on their approach
they were asked to maintain it for all the patients that were
recruited.
Treatment plan and outcome measures
Patients were randomly assigned to either DAiS – Dexamethasone
2mg per day, aspirin 75mg per day, Diethylstilbestrol 1mg per day
with ranitidine 150mg two times per day, until symptomatic or
PSA progression, or to DAdS – Dexamethasone 2mg per day and
aspirin 75mg per day with ranitidine 150mg two times per day. In
the DAdS arm, Diethylstilbestrol was added on PSA progression
that was confirmed 1 week later.
Time to PSA progression was determined using the PCWG 1
criteria (Bubley et al, 1999); for patients who achieved at least a
50% decrease in PSA, progression was defined as an increase in
PSA of at least 50% above the nadir with an absolute increase of
5ngml
 1. For those with less than 50% decrease in PSA, PSA
progression was defined as an increase of at least 25% above the
nadir, or in the absence of a PSA decrease, an increase of at least
25% above baseline. In either case, the increase had to be an
absolute value of at least 5ngml
 1. For the DAdS group, PSA
response was defined if a patient responded at least once either
before receiving Diethylstilbestrol or after. The use of bispho-
sphonates was permitted throughout the study. The time to
progression (TTP) was defined as the time from randomisation to
the first observation of disease progression. Progression-free
survival was defined as the time from randomisation to the first
observation of disease progression or death. In the DAdS group,
those who received Diethylstilbestrol at the progression of disease,
their TTP (PFS) was measured from randomisation to the first
observation of disease progression (progression or death) after
receiving Diethylstilbestrol. Survival time was measured from the
randomisation into the study drug to date of death. Patients with
no record of death up to the end of study were censored at their
last date of assessment.
Assessments
Patients were assessed monthly and were asked to complete a
quality of life assessment as part of the study – EORTC QLQ C30
with site-specific module PR25, which specifically assessed lower
urinary tract symptoms and erectile function. They were weighed
at each appointment and had blood drawn for PSA, urea and
electrolytes, liver function, and bone profile. Toxicity was recorded
using the NCI Common Toxicity Criteria version 3.0. Patients who
developed VTEs were recommended to continue hormonal therapy
and start low-molecular weight heparin, and then oral anti-
coagulants (warfarin).
Following progression of disease, the patients were treated at
the discretion of their physician or urologist. Information collected
at initial assessment included haemoglobin, raised alkaline
phosphatase (X130IUl
 1), previous therapy (categorised as:
GnRH, AA, maximum androgen blockade (MAB), radical treatment
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s(radiotherapy and surgery)), and comorbidities (diabetes, myo-
cardial infarction, and respiratory disease).
Statistical analysis
The sample size was determined to detect a clinically important
difference (at least 15%) in response rate between the two study
arms. On the basis of the observed response rate to Dexametha-
sone, 2mg of 62% (Nishimura et al, 2000) and the response to
Diethylstilbestrol, 1mg with corticosteroid of 78% (Farrugia et al,
2000), to detect a 16% difference (62 vs 78%) between the two
groups with 80% power, and 1:1 randomisation would require 130
patients in each arm (allowing for two dropouts in each arm) at 5%
level of significance. This was achieved using a two-sided w
2-test
(Machin et al, 2008)). This size of the trial also has 85% power to
detect 2 months difference between median TTP according to log-
rank test. Many investigators are finding that generally 5–10%
change in overall quality of life score (1–100 scale) is considered
significant by the patients. Therefore, it was assumed that 10%
difference in overall quality of life change score between two
treatment methods would be clinically important. The study would
have 62% power to detect this difference with this specified sample
size.
During the study, there was a period of time when the supply of
Diethylstilbestrol was suspended and 12 patients required an
alternative oestrogen. Therefore, an additional 12 patients were
recruited to safeguard the power of the trial and an intention-to-
treat analysis was performed based on all randomised patients.
Univariate analyses were performed to examine differences in
baseline characteristics between the two treatment groups (DAdS
vs DAiS) using w
2, two-sample t-tests, or Fisher’s exact tests, as
appropriate. Similarly, differences in toxicity between DA and
DAiS were tested using w
2, two-sample t-tests, or Fisher’s exact
tests, as appropriate. The baseline hazard/risk of VTE was plotted
using kernel density estimation, based on the DAiS group.
Univariate survival was examined using unadjusted Kaplan–
Meier curves, with comparison between DAiS and DAdS by using
the log-rank test. Stratified Cox proportional hazards model was
applied to test the effect of treatment on overall survival adjusting
for prognostic factors, including age, haemoglobin, alkaline
phosphatise, previous therapy, Gleason score, and comorbidities.
Pre-study androgen deprivation was highly correlated with the
pre-treatment therapy. Therefore, only pre-treatment therapy was
included in the multivariable Cox model. Regression diagnostics
included Schoenfeld residuals. The sample was confined to
complete cases for the multivariable analysis with no missing
values in the considered prognostic factors. To assess selection
bias because of restriction on complete cases, sensitivity analysis
was performed.
Multivariate analysis of variance (MANOVA) was performed to
see the effect of the two treatment approaches towards the quality of
life (based on EORTC QLQ-C30) and prostate-specific quality of life
(based on EORTC QLQ-PR-25). Percentage of change of scores from
baseline was calculated for each repeated measurements and then
they were averaged over the repetitions to apply MANOVA to test
the differences in quality of life measures in terms of treatment DAdS
vs DAiS. Intercooled STATA 10.1 (StataCorp., College Station, TX,
USA) for Windows was used for the statistical analysis.
RESULTS
Patient characteristics
The patient characteristics at study entry are shown in Table 1. The
median age was 76 years (inter-quartile range (IQR): 70–80) and
76% had positive bone scans. The median PSA before study entry
was 79.2ngml
 1 (IQR: 179ngml
 1) and 39.2% had a raised
(X130IUl
 1) alkaline phosphatase levels. Approximately 73% of
patients had received a GnRH as their initial form of androgen
deprivation. Approximately 62% of patients had previously norma-
lised their PSA (o4.5ngml
 1) to earlier androgen deprivation.
The median time from starting androgen deprivation to study
entry was 35 months (59 months for those with locally advanced
disease and 29 months in those with metastatic disease). Among
the non-metastatic group, median pre-study androgen depriva-
tion for the DAiS group (41 months) was significantly lower
than the 78 months for the DAdS group (P¼0.02). However, this
is based on only 19 patients in each group and hence is not
unexpected. Approximately 47% of patients continued androgen
deprivation with a GnRH. Approximately 22% of patients had
previous comorbidity (previous myocardial infarction, diabetes, or
chronic obstructive pulmonary disease). The study flow diagram
(CONSORT) is shown in Figure 1.
Response to therapy
The 50% PSA response to therapy was recorded according to the
PCWG criteria-1 (Bubley et al, 1999). Overall, 68% of patients
allocated to DAiS achieved a response as opposed to 64% of
patients allocated to DAdS (P¼0.49). Seven patients (2.7%) were
not evaluable for response. There were two early deaths, three early
withdrawals because of toxicity, and in two patients the data was
insufficient to evaluate response. Similar to the response rate,
neither the TTP nor the PFS differed significantly between the
DAiS and DAdS groups (P40.70) (Table 2). However, the response
rate for the DAiS (68%) was significantly higher than the response
rate of DA (before adding Diethylstilbestrol) (50%) (P¼0.002).
Similarly, the median TTP for DAiS (8.6 months) was significantly
longer than that of DA (4.5 months) (Po0.001). The response to
the addition of Diethylstilbestrol in those initially allocated to DA
was 43%, with a median duration of this response of 5 months.
A significant proportion of patients in this group who could have
received Diethylstilbestrol did not (35%), the most common
reason for this was toxicity on DA. All patients in the DAiS
remained castrate throughout therapy, however 22% of patients
allocated DAdS became non-castrate before the addition of
Diethylstilbestrol. Their median overall time to progression was
8.4 months in this group (95% CI: 7.4–22.1) vs 8.3 (95% CI:
6.7–9.0) in the group that remained castrate (P¼0.071, log-rank test).
The overall survival from entry in to the study was 19.1 months
(95% CI: 16.8–21.4). There was no significant difference in overall
survival when comparing the two arms; 19.4 months (95% CI:
16.8–25.9) in the DAiS arm and 18.8 months (95% CI: 15.8–20.4)
in the DAdS arm. (P¼0.28) (Figure 2).
Patients received subsequent chemotherapy at the choice of the
treating physician. In the DAdS group, 30% went on to have
chemotherapy and their median survival was 20.0 months (95% CI:
15.8–30.1) compared with 19.1 months (95% CI: 13.5–22.1),
(P¼0.53). In the DAiS group, 35% went on to receive
chemotherapy and their median survival was 19.5 months (95%
CI: 15.4–25.9) compared with 24.1 months (95% CI: 11.9–could
not be estimated) (P¼0.5).
Multivariable analysis using the Cox model (Table 3) showed
that age was associated with an increased risk of death. Among
other prognostic factors, having haemoglobin greater or equal to
11gdl
 1 decreased the risk of death significantly (HR 0.44, 95% CI:
0.25–0.77). Previous therapy had a significant effect on overall
survival (P¼0.01). Patients treated with AA alone had greater than
5 five times more risk of death compared with patients treated with
GnRH. Although previous therapy and haemoglobin had signifi-
cant effect on patients’ overall survival, treatment sequence (DAiS
vs DAdS) did not have any significant effect on survival when
adjusted for other baseline factors (P¼0.16). Sensitivity analysis,
carried out to check for selection bias because of complete case
analysis, showed that complete case analysis was unbiased.
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sOverall, 12 patients required oestrogen substitution because of
the manufacturing shortage of Diethylstilbestrol. Therefore, the
multivariable analyses were also repeated by excluding these
patients, per protocol analysis, but no difference in terms of
response rate, TTP and PFS, as well as in overall survival between
DAiS and DAdS was found.
Toxicity
The toxicity was compared between DAiS and DA (before adding
Diethylstilbestrol) in Table 4. The most serious events were
those due to VTE. The incidence of these was 22% (n¼28) in
DAiS and 11% (n¼14) in the DA arm (P¼0.02). In the DAds
arm, three VTEs occurred, whilst on Dexamethasone and
aspirin alone, 11 occurred following the addition of Diethyl-
stilbestrol. One TIA occurred on DAiS. The risk of VTEs varied
with time on treatment. The risk reached a maximum after
5 months of therapy and then tailed off; see Figure 3. In 60% of
patients, it was possible to anticoagulate and to continue hormonal
therapy.
Painful gynaecomastia occurred in only 1% on DA and in 40%
on DAiS (P¼0.001). Fluid retention was more common in DaiS,
although it occurred in DA as well (49 vs 42%: P¼0.26). Overall
dose reductions were made in 34% of patients (39% on the DA arm
and 30% on the DAiS arm P40.05). No significant differences
in weight gain were seen in the two arms (11% on DA and 14.0%
on DAS: P¼0.47).
Quality of life
Multivariate analysis of variance showed no significant differences
in quality of life measures of the QLQ-C30 questionnaire bet-
ween the two treatment arms over time, although pre-study
performance status had a significant effect on their quality of
life (Table 5). However, the sample data (see Table 6) showed
that the patients in DAiS group felt that they had slightly
better global health and sleep compared with the patients in
DAdS group. Similarly, there was no significant difference in
prostate-specific symptoms of the EORTC-PR25 between the
two treatment arms over the study time (MANOVA: Wilks’ l,
F5,106¼0.97, Po0.66). However, sample data showed that patients
in DAiS group felt that wearing an incontinence aid posed more
problems for them compared with the patients in DAdS group
(see Table 7).
DISCUSSION
This study reports that the treatment strategies of immediate vs
deferred Diethylstilbestrol do not differ significantly in terms of
efficacy in the management of CRPC. Despite a slightly higher
(nonsignificant) PSA response rate (68%) in the DAiS arm (with
immediate use of Diethylstilbestrol), deferring its use until failure
of Dexamethasone and aspirin (response rate 64%) might be the
preferred strategy as PFS, overall survival, and quality of life did
not reduce significantly, and there was a significantly reduced
number of VTEs and painful gynaecomastia. Previous therapy and
Table 1 Patients’ characteristics at presentation
Patient characteristics All (N¼269) DAdS (N¼133) DAiS (N¼136) P-value
*
Age: median (IQR), year 76 (10) 76 (11) 75.5 (10.5) 0.22
Initial PSA:
Median (IQR), ngml
 1 79.2 (179) 76.7 (176) 81.1 (193.7) 0.34
Pre-study androgen deprivation: median (IQR), month
Non-metastatic 59 (49) 78 (38) 41 (40) 0.02
Metastatic 29 (39) 34 (54) 27 (29) 0.29
No./total (%) No./total (%) No./total (%)
Metastatic disease 204/269 (76) 102/133 (77) 102/136 (75) 0.77
Gleason 0.72
p6 44/216 (20.4) 23/112 (20.5) 21/104 (20.2)
7 55/216 (25.4) 26/112 (23.2) 29/104 (27.9)
8–10 117/216 (54.2) 63/112 (56.3) 54/104 (51.9)
Initial therapy 0.86
GNRH 188/259 (72.6) 92/130 (70.8) 96/129 (74.4)
MAB 19/259 (7.3) 11/130 (8.4) 8/129 (6.2)
AA 13/259 (5.0) 8/130 (6.2) 5/129 (3.9)
Surgery 21/259 (8.1) 10/130 (7.7) 11/129 (8.5)
RT 18/259 (7.0) 9/130 (6.9) 9/129 (7.0)
Raised (X130IUl
 1) alkaline phosphatase 83/212 (39.2) 39/103 (37.9) 44/109 (40.4) 0.71
Haemoglobin (X11gdl
 1) 273/269 (88.1) 117/133 (88.0) 120/136 (88.2) 0.95
Performance status 1.00
0 95/269 (35.3) 47/133 (35.3) 48/136 (35.3)
1–3 174/269 (64.7) 86/133 (64.7) 88/136 (64.7)
Positive bone scan 204/269 (75.8) 102/133 (76.7) 102/136 (75) 0.75
PSA normalised 167/269 (62.1) 82/133 (61.7) 85/136 (62.5) 0.89
Previous chronic disease
Myocardial infarction 12/194 (6.2) 8/101 (8) 4/93 (4.3) 0.38
Diabetes mellitus 10/194 (5.2) 3/101 (3) 7/93 (7.5) 0.20
Respiratory 23/194 (11.9) 15/101 (14.9) 8/93 (8.6) 0.18
Abbreviations: AA¼anti-androgen; DAiS¼Dexamethasone, Aspirin, and immediate addition of Diethylstilbestrol; DAdS¼Dexamethasone, Aspirin, and deferred (until disease
progression) Diethylstilbestrol; GnRH¼gonadorelin analogue; IQR¼inter-quartile range; MAB¼maximum androgen blockade; PSA¼prostate-specific antigen; RT¼
radiotherapy. *P-values refer to differences between patients receiving DAdS and DAiS.
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shaemoglobin had significant effect on patients’ overall
survival rather than the treatment when adjusted for other
baseline prognostic factors. Treatment sequencing did not affect
the quality of life but pre-treatment performance status did.
However, the response rate for the DAiS (68%) was significantly
higher than the response rate of DAdS (before adding Diethyl-
stilbestrol) (50%) (P¼0.002). Similarly, the median TTP for DAiS
(8.6 months) was significantly longer than that of DAdS
(4.5 months) (Po0.001).
The failure to mandate continuous gonadorelin therapy
throughout the trial has meant that some patients were not
biochemically castrate in the DAdS arm. This could be considered
as a shortcoming of the study – and in 22% of cases, testosterone
recovery did occur, however this group’s overall time to
progression was the same as those who remained castrate, which
was reassuring.
Reduction in PSA by 50% was associated with an overall survival
advantage (Table 2). Recently, the importance of the reduction in
PSA with chemotherapy has been questioned. Indeed, in the
recently updated guidelines for reporting of Phase II studies in
CRPC (Scher et al, 2008), the quoting of a PSA 50% reduction rate
has been abandoned. It would seem that this might be premature
wherein the agent concerned targets the androgen receptor as
opposed to functioning independently of it.
Quality of life was assessed monthly during this study and there
was no improvement conferred by the immediate use of Diethyl-
stilbestrol. In particular, the PR25 prostate-specific questionnaire
failed to show an improvement, suggesting that lower urinary tract
Assessed for eligibility
(n=274)
Excluded four:two did not 
meet inclusion criteria
and two refused to participate
Per-protocol patients=128
Intention-to-treat analysis: (n=133)
(Alive 45 and dead 88)
Lost to follow-up: 0
Allocated to DAdS: 133
Received allocated intervention: 128
Did not receive allocated intervention: 5
(owing to manufacturing shortage of
diethylstilbestrol)
Lost to follow-up: 1
Allocated to DAiS: 137
Received allocated intervention: 129
Did not receive allocated intervention: 7
(owing to manufacturing shortage of
diethylstilbestrol) and lost to follow-up: 1
Per-protocol patients= 129
Intention-to-treat analysis: (n=136)
(Alive 62 and dead 74)
Allocation
Follow-up
Analysis
Enrolment
270 patients
randomised
Figure 1 The consort flow diagram.
Table 2 Response to immediate (concurrent) vs deferred (sequential) Diethylstilbestrol
All (N¼262) DAdS (N¼129) DAiS (N¼133) P-value
PSA response, no. (%) 174 (66) 83 (64) 91 (68) 0.49
Median TTP in months (95% CI) 8.5 (7.7–10.0) 8.4 (7.6–10.4) 8.6 (5.7–10.9) 0.88
Median PFS in months (95% CI) 8.1 (7.1–8.8) 8.1 (7.4–9.0) 8.1 (5.3–10.0) 0.71
OS in months (95% CI) 19.1 (16.8–21.4) 18.8 (15.8–20.4) 19.4 (16.8–25.9) 0.28
PSA response Median OS
Respondent (95% CI) 26.2 (20.1–32.2) o0.001
Non-respondent (95% CI) 11.6 (9.7–13.6)
DA DAiS
PSA response, no. (%) 174 (66) 64 (50) 91 (68) 0.002
Median TTP in months (95% CI) 5.3 (4.6–6.4) 4.5 (3.1–4.8) 8.6 (5.7–10.9) o0.001
Abbreviations: CI¼confidence interval; DA¼Dexamethasone and Aspirin; DAiS¼Dexamethasone, Aspirin, and immediate addition of Diethylstilbestrol;
DAdS¼Dexamethasone, Aspirin, and deferred (until disease progression) Diethylstilbestrol; OS¼overall survival; PSA¼prostate-specific antigen; TTP¼time to progression.
Immediate vs deferred addition of Diethylstilbestrol
J Shamash et al
624
British Journal of Cancer (2011) 104(4), 620–628 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
ssymptoms were not helped by Diethylstilbestrol specifically. As in
many studies, quality of life assessment has its limitations; there
was a 26% failure to complete the forms, but this was not related to
treatment (equally distributed between the two arms).
Overall, the treatments were reasonably tolerated. Diethylstilbestrol
and Dexamethasone given together were associated with increased
toxicity. The development of VTE was associated with the use of
Diethylstilbestrol, although at this relatively low dose, the rate was
manageable with no suggestion of excess mortality in this study.
Moreover, many patients were able to continue Diethylstilbestrol with
Log-rank test P = 0.14
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Figure 2 Overall survival according to immediate vs deferred
Diethylstilbestrol.
Table 3 Multivariable Cox proportional hazards model for concurrent vs
sequential treatment based on overall survival (stratified by performance
status, PSA response to previous therapy and bone scan)
a
Characteristic Hazard ratio (95% CI)
b P-value
Age (in years) 0.70 (0.49–1.00) 0.051
Age square 1.0025 (1.00049–1.00502) 0.046
Treatment 0.16
DAdS 1
DAiS 0.69 (0.41–1.16)
Haemoglobin 0.004
o11gdl
 1 1
X11gdl
 1 0.44 (0.25–0.77)
Alkaline phosphatase 0.93
o1.5 ULN 1
X1.5 ULN 0.97 (0.55–1.71)
Gleason 0.49
p61
7 0.82 (0.40–1.71)
8–10 0.68 (0.35–1.30)
Prior therapy 0.01
GnRH 1
AA 5.38 (1.99–14.58)
MAB 1.91 (0.90–4.07)
Radical treatment
(radiotherapy or surgery)
1.38 (0.76–2.50)
Diabetes 0.44
Absent 1
Present 0.68 (0.25–1.81)
Myocardial infarction 0.13
Absent 1
Present 2.07 (0.81–5.27)
Respiratory disease 0.44
Absent 1
Present 0.73 (0.33–1.62)
Abbreviations: AA¼anti-androgen; DAiS¼Dexamethasone, Aspirin, and immediate
addition of Diethylstilbestrol; DAdS¼Dexamethasone, Aspirin, and deferred (until
disease progression) Diethylstilbestrol; CI¼confidence interval; GNRH¼gonadorelin
analogues; MAB¼maximum androgen blockade; PSA¼prostate-specific antigen;
ULN¼upper limit of normal.
aAnalysis was restricted to patients without missing
values (n¼164).
bHazard ratios are adjusted for all variables displayed in the table.
Table 4 Comparison of toxicity between DA and DAiS
All (N¼257) DA (N¼128) DAiS (N¼129)
Toxicity N (%) N (%) N (%) P-value
Painful
gynaecomastia
52 (20) 1 (01) 51 (40) o0.001
Headaches 28 (11) 16 (13) 12 (09) 0.31
Skin 134 (52) 59 (46) 65 (50) 0.52
Fluid retention 117 (46) 54 (42) 63 (49) 0.26
Weight gain 32 (13) 14 (11) 18 (14) 0.47
Myopathy 5 (02) 4 (03) 1 (01) 0.25
Hyperglycaemia 4 (02) 3 (02) 1 (01) 0.51
VTE 42 (16) 14 (11) 28 (22) 0.02
DVT 20 (08) 3 (03) 17 (13)
PE 21 (08) 11 (09) 10 (08)
TIA 1 (0.5) 0 (0) 1 (01)
Abbreviations: DA¼Dexamethasone and Aspirin; DAiS¼Dexamethasone, Aspirin,
and immediate addition of Diethylstilbestrol; DVT¼deep venous thrombosis;
PE¼pulmonary embolism; TIA¼transient ischaemic attack; VTE¼veno–thrombo-
embolic disease.
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Figure 3 The risk of veno-thromboembolic events (VTE) from start of
Diethylstilbestrol therapy over time.
Table 5 Multivariate analysis of variance based on EOTC-QLQ-C30 in
terms of immediate vs deferred Diethylstilbestrol and other stratifying
factors
Factor Statistic d.f. F(d.f.1,d.f.2) P-value
Treated with DAiS 0.91 1 1.01(15, 159) 0.44
Bad performance 0.85 1 1.83(15, 159) 0.03
Metastatic disease 0.87 1 1.59(15, 159) 0.08
PSA normalised 0.89 1 1.30(15, 159) 0.21
Abbreviations: DAiS¼Dexamethasone, Aspirin, and immediate addition of
Diethylstilbestrol; d.f.¼degrees of freedom; PSA¼prostate-specific antigen.
Model (Wilks l): F(df1, df2)¼1.55(60, 623), P-value¼0.007.
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sconcomitant anticoagulation. There were no documented myocardial
infarcts or development of angina on this agent.
Dexamathasone and aspirin was well tolerated with good
response rates (50%). The most common toxicities were bruising
and fluid retention. It is surprising that so many developed fluid
retention, as Dexamethasone is considered to be a pure
glucocorticoid. It is possible that the use of aspirin at the same
time influenced this. Overall, 34% required dose reduction of
Dexamethasone, and clearly as lower doses can produce PSA
responses, starting with a smaller dose and escalating might be an
alternative strategy, particularly in asymptomatic patients with
rising PSA. Several groups (Nishimura et al, 2000; Venkitaraman
et al, 2008), have demonstrated the value of low-dose Dexametha-
sone (500m.c.g. per day) in terms of efficacy and toxicity.
However, there is a suggestion of a PSA response to increasing
doses (Nishimura et al, 2000). In patients with symptomatic
disease, the improvement in appetite and weight that result from a
higher dose of Dexamethasone might be more appealing, as dose
escalation takes time.
When reviewed for prognostic factors, it is clear that previously
identified prognostic factors from other studies apply here
(Hussain et al, 2006). We could not identify a particular subgroup
that benefitted from either treatment approach. The effect of pre-
treatment haemoglobin was particularly striking with a hazard
ratio of 0.44 (P¼0.004) for overall survival, confirming the finding
in many cancers that the development of anaemia is a strong
adverse prognostic factor. Patients treated with AAs monotherapy
fared worse, despite the fact that they needed to be biochemically
castrate before study entry (via addition of GnRH analogue).
Until recently, there was a feeling that further hormone
manipulations beyond androgen deprivation offered little other
than transient falls in PSA, and that docetaxel-based chemotherapy
should be offered for a majority following the failure of
conventional androgen deprivation. It is becoming clearer that
major benefits might be obtained with further hormone therapies;
the interest in the drug abiraterone is supportive of this (Attard
et al, 2009).
This study sheds some light on the immediate vs deferred
addition of Diethylstilbestrol with Dexamethasone and Aspirin in
treating patients with CRPC. Current thinking attributes prostate
cancer growth and development to stimulation of the androgen
receptor even at low-plasma testosterone levels (Attard et al, 2008).
Others speculate that mutations may confer a broader range of
potential ligand binding (Grigoryev et al, 2000; Sun et al, 2006),
including corticosteroids and oestrogens. This hypothesis would
explain the findings of this study, in that both drugs bind to the
AR, but that Diethylstilbestrol has broader activity. To prove this,
it would be necessary to reverse the sequence of study drugs,
however, the fact that Dexamethasone has fewer severe side effects
makes this unattractive.
It is possible that response to Diethylstilbestrol may have
required the presence of Dexamethasone. It would have been
impractical to insist that Dexamethasone be removed when
Diethylstilbestrol started, in view of the fact that many would
have been on it for some time making rapid withdrawal unsafe. It
would have been useful to measure adrenal androgens and their
precursors during the study to see whether they were related to
response, and this and the addition of other translational end
points would have strengthened the study. Several other short-
comings of the study were apparent. The study commenced before
the docetaxel era making its usage infrequent in the study,
although its use became more frequent as the study progressed. It
is unclear whether this affected the outcome. In addition, the
recent publication of two studies have lead to the conclusion that
radiotherapy has a valuable role in the management of patients
with locally advanced disease, suggesting that the number of such
patients requiring systemic treatment for local progression will fall
(Mottet et al, 2010; Warde et al, 2010). Disproportionate dose
reduction of Dexamethasone (39% on the DA arm and 30% on the
DAiS arm, P¼0.12) might affect the study outcome slightly.
Finally, as study entry required a rise in PSA, rather than
progression on imaging, patients whose prostate cancer did not
express PSA were not included.
In conclusion, the immediate or deferred use of Diethylstilbes-
trol with Dexamethasone to manage CRPC differs neither in terms
of PSA response rate nor in terms of PFS. Moreover, there was no
suggestion of significant difference in overall survival or in quality
of life. Given the significantly higher toxicity of Diethylstilbestrol,
deferring Diethylstilbestrol until failure of Dexamethasone is the
preferred strategy when using these agents in CRPC. The use of
hormonal agents following failure of chemotherapy for what was
previously termed as hormone refractory disease is becoming
more accepted (Shamash et al, 2008), and the use of such agents
post chemotherapy warrants further investigation.
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